- Dosage: Artemether/Lumefantrine 80/480mg
- Packaging: 6 tablets/blister*10/box
- Shelf Life: 36months
Package:
Product Description
Artemether Lumefantrine 80/480mg Tablets: What the Published Guidance Says
Artemisinin-based combination therapy is the WHO-recommended backbone of falciparum malaria treatment.
Before Artemether Lumefantrine 80/480mg Tablets is quoted, we confirm the monograph, the strength on the artwork and the release testing required by your market — the points summarised here.
- ACT is the treatment of choice in all trimesters For uncomplicated P. falciparum malaria, MSF medical guidelines state the treatment of choice in all trimesters is an artemisinin-based combination therapy taken for three days. Co-formulated and co-blistered regimens are both described, including artemether/lumefantrine 20/120 mg and 80/480 mg, artesunate/amodiaquine, artesunate/mefloquine and dihydroartemisinin/piperaquine. MSF Medical Guidelines — Malaria (Chapter 4.3, Parasitic infections)
- The ACT combinations and their strengths are specified on the WHO Model List Section 6.5.3.1 of the 24th WHO Model List (2025) specifies the curative antimalarials, including artemether + lumefantrine tablet 20 mg + 120 mg and a dispersible tablet, artesunate + amodiaquine, artesunate + mefloquine, artesunate + pyronaridine as granules and tablets, dihydroartemisinin + piperaquine across four tablet strengths, and artesunate co-packaged with sulfadoxine + pyrimethamine. WHO Model List of Essential Medicines, 24th List (2025) — report of the 25th WHO Expert Committee (TRS 1064)
- For severe malaria, parenteral artesunate is the drug of choice WHO guidance is artesunate 2.4 mg/kg by intravenous or intramuscular injection on admission, again at 12 and 24 hours, then once daily. Where artesunate is unavailable, intramuscular artemether 3.2 mg/kg on admission followed by 1.6 mg/kg daily is the alternative — artemether must never be given by the intravenous route. Parenteral treatment continues for at least 24 hours before switching to a full three-day oral ACT course. WHO — Malaria case management: operations manual
These points are quoted because they shape how Artemether Lumefantrine 80/480mg Tablets is specified, labelled and purchased — including strength selection, pack size and the artwork wording. Confirm each one against the approved product information in your market before finalising a purchase order.
Supply & Specification Data for Artemether Lumefantrine 80/480mg Tablets
| Product Name | Artemether + Lumefantrine Tablets (Artemether 80mg + Lumefantrine 480mg Combination Tablets) |
| Specification | Each tablet contains: Artemether 80mg + Lumefantrine 480mg |
| Dosage Form | Oral Film-Coated Tablet (for oral administration) |
| Active Ingredient | Artemether + Lumefantrine (benflumetol) |
| Pharmacological Class | Antimalarial / Artemisinin Combination Therapy (ACT) |
| Route of Administration | Oral administration (swallowed whole with water; take with food or milk to enhance absorption). |
| Storage | Store below 25°C, in a dry place, protected from light and moisture. Keep blister pack sealed until use. Do not freeze. |
| Therapeutic group | Malaria & ACTs — Malaria & ACTs |
| Manufacturer | Sinophare Bio-technology Co., Ltd. (GMP, China) |
| Documentation supplied | COA, HPLC/GC data, stability data, dossier package |
The same therapeutic range is supplied in several presentations, so one purchase order can cover a mixed requirement: Chloroquine Phosphate 500mg Tablets, Dihydroartemisinin 40mg + Piperaquine 320mg Tablets, Sulfadoxine/Pyrimethamine 175mg + Amodiaquine 75mg, Sulfadoxine Pyrimethamine 175mg + Dihydroartemisinin 60mg, Artesunate 200mg + Amodiaquine 600mg Tablets, Artesunate 400mg Mefloquine 500mg Tablets, Artesunate Suppositories 100mg, Artemether 80mg Injection.
Testing, Monographs & Batch Documentation
Products are manufactured and tested against USP, EP, BP and CP monographs, with incoming raw-material inspection, in-process monitoring and full finished-product testing.
Artemether Lumefantrine 80/480mg Tablets is released against the pharmacopoeial monograph named on your order (USP, EP, BP or CP). Where no monograph exists for the exact presentation, the specification is agreed with you in writing before manufacture and is attached to the certificate of analysis.
Standardised GMP production workshops with an independent R&D laboratory and a complete quality-inspection centre.
The batch record for this product normally includes:
- Testing for packaging integrity and seal testing
- Testing for description and identification
- Testing for assay of the active substance
- Testing for related substances and impurities
- Testing for dissolution or release profile (solid oral forms)
- Testing for uniformity of dosage units
COA, HPLC and GC data, DMF and dossier packages, plus registration support documents for national marketing-authorisation filings.
Pack Configuration, Artwork & Shipping Documents
- Pack size: Blister pack (PVC-Alu), typically 24 tablets per box (6 treatment courses of 4 tablets each). Non-standard pack sizes can be quoted against your artwork.
- Storage: Store below 25°C, in a dry place, protected from light and moisture. Keep blister pack sealed until use. Do not freeze..
- Shelf life: 36 months (unopened). Stability data for the marketed pack is included in the dossier.
- Labelling: we typeset the carton and leaflet in English, Arabic, French, Russian and Spanish and in any further language your market requires, carrying your own brand where the local rules allow.
- Export: commercial invoice, packing list, certificate of origin, GMP certificate, COA and the free-sale certificate issued by the country of manufacture whenever your customs or regulator asks for it.
Dossier, Authority Filings & Tender Documentation
Sinophare Bio-technology Co., Ltd. holds DML Number Jin20160068 (medicines) and Jin20160069 (paracetamol API).. That registration identifies the legal manufacturer on the certificate of analysis, the GMP certificate and the documents filed with your national medicines authority.
- Site Master File and GMP certificate for the manufacturing workshops.
- Method validation, stability protocol and the shelf-life justification for the marketed pack.
- Answers to authority questions during assessment, handled by the regulatory contact who prepared the file.
- Tender and framework documentation, including pre-qualification questionnaires and sample logistics.
- Artwork and mock-up approval pack, showing the carton, label and leaflet exactly as they will be printed for your market.
This page describes Artemether Lumefantrine 80/480mg Tablets as a product of the ACT regimens named in the WHO Model List of Essential Medicines family. A WHO or national listing is a supply-context fact, not an approval in your market; marketing authorisation remains specific to each country.
Buyer Questions about Artemether Lumefantrine 80/480mg Tablets
What pack size is available for Artemether Lumefantrine 80/480mg Tablets?
The reference pack is Blister pack (PVC-Alu), typically 24 tablets per box (6 treatment courses of 4 tablets each). Non-standard blister, bottle and carton configurations are quoted against your artwork, matched to the stability data already held for the presentation.
What documentation comes with a shipment of Artemether Lumefantrine 80/480mg Tablets?
Each batch ships with a certificate of analysis covering description, identification, assay and related substances, plus stability data for the marketed pack and the GMP certificate of the manufacturing site. Shelf life: 36 months.
Does the batch documentation for Artemether Lumefantrine 80/480mg Tablets support a registration filing?
Each batch ships with a certificate of analysis covering description, identification, assay and related substances, plus stability data for the marketed pack and the GMP certificate of the manufacturing site. Shelf life: 36 months. The full CTD dossier and the authority assessment file are supplied as part of a registration order; routine shipments carry the COA and stability data only.
Which ACT combinations appear on the WHO Model List?
The 24th List (2025) specifies artemether + lumefantrine, artesunate + amodiaquine, artesunate + mefloquine, artesunate + pyronaridine, dihydroartemisinin + piperaquine, artesunate co-packaged with sulfadoxine + pyrimethamine, and chloroquine restricted to P. vivax.
Do you supply dispersible paediatric ACTs?
Yes. We supply dispersible and dry-suspension presentations aligned to the strengths in the Model List, including artemether + lumefantrine 20/120 mg dispersible tablets and paediatric suspensions.
Other Malaria & ACTs Products in This Range
- Chloroquine Phosphate 500mg Tablets — 500mg
- Dihydroartemisinin 40mg + Piperaquine 320mg Tablets — 40mg
- Sulfadoxine/Pyrimethamine 175mg + Amodiaquine 75mg — 175mg
- Sulfadoxine Pyrimethamine 175mg + Dihydroartemisinin 60mg — 175mg
- Artesunate 200mg + Amodiaquine 600mg Tablets — 200mg
- Artesunate 400mg Mefloquine 500mg Tablets — 400mg
Browse the full Malaria & ACTs range; all Tablets; the complete product catalogue.
Request a Quotation for Artemether Lumefantrine 80/480mg Tablets
Send the specification, pack size, quantity and destination market for Artemether Lumefantrine 80/480mg Tablets 80mg and we will confirm availability, lead time and documentation. Tender quantities and registration samples are handled on the same quotation.
Sources & Regulatory Notes
- MSF Medical Guidelines — Malaria (Chapter 4.3, Parasitic infections)
- WHO Model List of Essential Medicines, 24th List (2025) — report of the 25th WHO Expert Committee (TRS 1064)
- WHO — Malaria case management: operations manual
Reference information only. The published guidance summarised on this page is quoted for professional and regulatory-context purposes and does not constitute medical advice, a prescribing recommendation or a promotion of any product for a particular indication. Prescribing decisions must follow the approved product information and national treatment guidelines in the market of use.

